Mylan CEO Heather Bresch is expected to refuse to lower the $600 price of the allergy drug EpiPen at a congressional hearing Wednesday.
Bresch is scheduled to appear before the House Oversight and Government Reform Committee to address concerns over a price increase of 400 percent for the life-saving allergy treatment. However, her opening statement does not include any promises of lowering the price or providing more discounts beyond what Mylan has already announced.
Real journalism.Trusted by millions.
Unlimited access to in-depth reporting, expert analysis, and the stories that shape our country.
Subscribe Now
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.